PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
复制标题
PD-L1 表达是乳腺癌术后患者基于 CIK 细胞的免疫治疗的预测生物标志物
DOI：
10.1186/s40425-019-0696-8
复制
发表时间：
2019-08-27
影响因子：
10.9
通讯作者：
Xia, Jian-Chuan
中科院分区：
文献类型：
--
作者：
Zhou, Zi-Qi;Zhao, Jing-Jing;Xia, Jian-Chuan
背景基于对患者人群的统计分析，放化/内分泌治疗和苦参碱诱导的杀伤细胞（CIK）输注的序贯组合已被证明是乳腺癌切除术后的有效治疗。然而，个体是否可以从基于CIK细胞的治疗中获得改善的预后仍然未知。在本研究中，我们专注于免疫微环境的调节，并专门研究PD-L1表达与CIK免疫治疗乳腺癌的生存效益之间的关系。方法共有310例接受综合治疗的乳腺癌术后患者参加了这项回顾性研究，其中对照组160例（接受化疗/放疗/内分泌治疗）和CIK细胞治疗组150例患者结果CIK治疗组的总生存期（OS）和无复发生存期（RFS）明显优于对照组。使用多变量生存分析显示，肿瘤组织切片中的PD-L1表达是CIK治疗组患者的独立预后因素。CIK组的进一步生存分析显示，PD-L1肿瘤表达患者的OS和RFS较长。此外，在所有患者中，谁参加了这项研究中，只有PD-L1表达的患者经历了生存的好处CIK treatment.ConclusionsOur研究显示PD-L1表达和CIK治疗之间的关系，并揭示了PD-L1在肿瘤中的表达是作为辅助CIK治疗乳腺癌术后的一个指标。
BackgroundA sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patient population. However, whether an individual could obtain an improved prognosis from CIK cell-based treatment remains unknown. In the present study, we focused on immune microenvironment regulation and specifically investigated the relationship between PD-L1 expression and survival benefit from CIK immunotherapy in breast cancer.MethodsA total of 310 postoperative breast cancer patients who received comprehensive treatment were enrolled in this retrospective study, including 160 patients in the control group (received chemotherapy/radiotherapy/endocrinotherapy) and 150 patients in the CIK cell treatment group (received chemotherapy/radiotherapy/ endocrinotherapy and subsequent CIK infusion).ResultsWe found that overall survival (OS) and recurrence-free survival (RFS) were significantly better in the CIK group than that in the control group. PD-L1 expression in tumor tissue sections was showed to be an independent prognostic factor for patients in the CIK treatment group using multivariate survival analysis. Further survival analysis in the CIK group showed that patients with PD-L1 tumor expression exhibited longer OS and RFS. In addition, among all patients who were enrolled in this study, only the patients with PD-L1 expression experienced survival benefits from CIK treatment.ConclusionsOur study showed the relationship between PD-L1 expression and CIK therapy and revealed that PD-L1 expression in the tumor is as an indicator of adjuvant CIK therapy for postoperative breast cancer.